Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2024-01-03 00:00:00 ET · period of report 2023-12-29 · accession 0001209191-24-000352 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-03 | 2023-12-29 | VERA | Fordyce Marshall | Pres, CEO, Dir | M - OptEx | $2.88 | +13.5K | 256.9K | +6% | +$38.9K |
| DM | 2024-01-03 | 2023-12-29 | VERA | Fordyce Marshall | Pres, CEO, Dir | M - OptEx | $0.00 | -13.5K | 874.2K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-12-29 | M | A | 516 | $2.32 | 243,877 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-12-29 | M | A | 13,000 | $2.90 | 256,877 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-12-29 | M | D | 516 | $0.00 | 0 | D | $2.32 · — to 2030-01-15 | 516 Class A Common Stock | (F1) 1/3 of the shares subject to the option vested on January 10, 2021, and 1/36 of the shares vest monthly thereafter. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-12-29 | M | D | 13,000 | $0.00 | 874,212 | D | $2.90 · — to 2030-12-15 | 13,000 Class A Common Stock | (F2) 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. |